ZA985352B - Barbituric acid derivatives with antimetastatic and antitumor activity. - Google Patents

Barbituric acid derivatives with antimetastatic and antitumor activity.

Info

Publication number: ZA985352B
Authority: ZA; South Africa
Prior art keywords: antimetastatic; acid derivatives; antitumor activity; barbituric acid; barbituric
Prior art date: 1997-06-21

Application number

ZA9805352A

Other languages

English (en)

Inventor

Ambrogio Oliva

Gianpiero De Cillis

Frank Grams

Valeria Livi

Gerd Zimmermann

Ernesto Menta

Hans-Willi Krell

Original Assignee

Roche Diagnostics Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-06-21

Filing date

1998-06-19

Publication date

1999-12-20

1998-06-19 Application filed by Roche Diagnostics Gmbh filed Critical Roche Diagnostics Gmbh

1999-12-20 Publication of ZA985352B publication Critical patent/ZA985352B/xx

Links

230000002001 anti-metastasis Effects 0.000 title 1
230000000259 anti-tumor effect Effects 0.000 title 1
150000007656 barbituric acids Chemical class 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/60—Three or more oxygen or sulfur atoms
- C07D239/62—Barbituric acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Life Sciences & Earth Sciences (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Rheumatology (AREA)
Hematology (AREA)
Hospice & Palliative Care (AREA)
Oncology (AREA)
Ophthalmology & Optometry (AREA)
Pain & Pain Management (AREA)
Diabetes (AREA)
Immunology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Saccharide Compounds (AREA)

ZA9805352A 1997-06-21 1998-06-19 Barbituric acid derivatives with antimetastatic and antitumor activity. ZA985352B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP97110200		1997-06-21

Publications (1)

Publication Number	Publication Date
ZA985352B true ZA985352B (en)	1999-12-20

Family

ID=8226939

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA9805352A ZA985352B (en)	1997-06-21	1998-06-19	Barbituric acid derivatives with antimetastatic and antitumor activity.

Country Status (18)

Country	Link
US (1)	US6335332B1 (de)
EP (1)	EP0989982B1 (de)
JP (1)	JP2002504916A (de)
KR (1)	KR20010014020A (de)
CN (1)	CN1295227C (de)
AR (1)	AR018997A1 (de)
AT (1)	ATE302200T1 (de)
AU (1)	AU746853B2 (de)
BR (1)	BR9810450A (de)
CA (1)	CA2294259A1 (de)
CO (1)	CO4940451A1 (de)
DE (1)	DE69831233T2 (de)
ES (1)	ES2247707T3 (de)
HR (1)	HRP980340A2 (de)
MA (1)	MA24573A1 (de)
TR (1)	TR199903148T2 (de)
WO (1)	WO1998058925A1 (de)
ZA (1)	ZA985352B (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AUPO190596A0 (en)	1996-08-26	1996-09-19	Alchemia Pty Ltd	Oligosaccharide synthesis
AUPO937597A0 (en) *	1997-09-24	1997-10-16	Alchemia Pty Ltd	Protecting and linking groups for organic synthesis
US6265578B1 (en) *	1999-02-12	2001-07-24	Hoffmann-La Roche Inc.	Pyrimidine-2,4,6-triones
PA8498701A1 (es) *	1999-08-12	2002-08-26	Pfizer Prod Inc	Pirimidina-2,4,6-trionas inhibidores de metaloproteinasas
EP1276728A2 (de)	2000-04-24	2003-01-22	ARYx Therapeutics	Ultrakurz wirksame hypnotische barbiturate
BR0114913A (pt) *	2000-10-26	2003-07-01	Pfizer Prod Inc	Inibidores de metaloproteinase de espiro-pirimidina-2,4,6-triona
US6841671B2 (en)	2000-10-26	2005-01-11	Pfizer Inc.	Spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors
IL154946A0 (en) *	2000-10-26	2003-10-31	Pfizer Prod Inc	Pyrimidine-2,4,6-trione metalloproteinase inhibitors
SE0100902D0 (sv)	2001-03-15	2001-03-15	Astrazeneca Ab	Compounds
ES2274043T3 (es) *	2001-05-03	2007-05-16	F. Hoffmann-La Roche Ag	Combinacion de un inhibidor de gelatina con un agente antitumoral y usos de la misma.
NI200300045A (es) *	2002-04-26	2005-07-08	Pfizer Prod Inc	Inhibidores de triariloxiariloxipirimidin-2,4,6-triona de metaloproteinasa.
JP2005529889A (ja)	2002-04-26	2005-10-06	ファイザー・プロダクツ・インク	ピリミジン−２，４，６−トリオンメタロ−プロテイナーゼ阻害剤
AU2003219410A1 (en)	2002-04-26	2003-11-10	Pfizer Products Inc.	Triaryl-oxy-aryl-spiro-pyrimidine-2, 4, 6-trione metalloproteinase inhibitors
AU2003216660A1 (en)	2002-04-26	2003-11-10	Pfizer Products Inc.	N-substituted-heteroaryloxy-aryl-spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors
EP1737464B1 (de) *	2004-04-01	2008-07-23	F. Hoffmann-La Roche AG	Verwendung von trioxopyrimidin zur behandlung und prävention von entzündlichen erkrankungen der bronchien
KR100837137B1 (ko) *	2004-04-01	2008-06-11	에프. 호프만-라 로슈 아게	기관지 염증성 질환의 치료 및 예방을 위한트리옥소피리미딘의 용도
NZ571803A (en)	2006-04-07	2011-12-22	Vertex Pharma	Amide indole derivatives as modulators of ATP-binding cassette transporters
US10022352B2 (en)	2006-04-07	2018-07-17	Vertex Pharmaceuticals Incorporated	Modulators of ATP-binding cassette transporters
US7645789B2 (en)	2006-04-07	2010-01-12	Vertex Pharmaceuticals Incorporated	Indole derivatives as CFTR modulators
USRE50453E1 (en)	2006-04-07	2025-06-10	Vertex Pharmaceuticals Incorporated	Indole derivatives as CFTR modulators
US8563573B2 (en)	2007-11-02	2013-10-22	Vertex Pharmaceuticals Incorporated	Azaindole derivatives as CFTR modulators
KR100862969B1 (ko)	2007-03-05	2008-10-13	바이오스펙트럼 주식회사	바르비투르산을 유효성분으로 포함하는 피부 미백제
US8802868B2 (en)	2010-03-25	2014-08-12	Vertex Pharmaceuticals Incorporated	Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
ES2608474T3 (es)	2010-04-22	2017-04-11	Vertex Pharmaceuticals Incorporated	Proceso de producción de compuestos indol cycloalkylcarboxamido
WO2014014841A1 (en)	2012-07-16	2014-01-23	Vertex Pharmaceuticals Incorporated	Pharmaceutical compositions of (r)-1-(2,2-diflurorbenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide and administration thereof
US10093631B2 (en)	2014-02-14	2018-10-09	Acquist Llc	Bifunctional compounds and use for reducing uric acid levels
ES2885181T3 (es)	2014-04-15	2021-12-13	Vertex Pharma	Composiciones farmacéuticas para el tratamiento de enfermedades mediadas por el regulador de la conductancia transmembrana de fibrosis quística
KR20170103803A (ko)	2015-01-22	2017-09-13	주니어 워렐 레이먼드 피.	요산 수준의 저감을 위한 이작용성 화합물 및 용도
TWI771303B (zh)	2016-06-30	2022-07-21	美商艾克奎斯特有限責任公司	化合物及其於降低尿酸位準之用途(一)
TWI749024B (zh)	2016-07-06	2021-12-11	美商艾克奎斯特有限責任公司	化合物及其於降低尿酸位準之用途
LV15384B (lv)	2017-07-24	2019-05-20	Latvijas Organiskās Sintēzes Institūts	1-Acetil-5-nitro-4-fenil-3-pirolin-2-ons pielietošanai vēža ārstēšanā

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP3083842B2 (ja) *	1989-11-14	2000-09-04	スローン・ケターリング・インスティテュート・フォー・キャンサー・リサーチ	新規かつ強力な最終分化誘発剤及びその使用方法
ES2106040T3 (es) *	1990-05-16	1997-11-01	Abbott Lab	Ensayo para barbituratos, trazadores, inmunogenos, anticuerpos y kit.
DE19548624A1 (de)	1995-12-23	1997-06-26	Boehringer Mannheim Gmbh	Neue Barbitursäure-Derivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel

1998
- 1998-06-18 AU AU85391/98A patent/AU746853B2/en not_active Ceased
- 1998-06-18 WO PCT/EP1998/003677 patent/WO1998058925A1/en not_active Ceased
- 1998-06-18 AT AT98936361T patent/ATE302200T1/de not_active IP Right Cessation
- 1998-06-18 EP EP98936361A patent/EP0989982B1/de not_active Expired - Lifetime
- 1998-06-18 DE DE69831233T patent/DE69831233T2/de not_active Expired - Fee Related
- 1998-06-18 CN CNB988083558A patent/CN1295227C/zh not_active Expired - Fee Related
- 1998-06-18 KR KR19997012049A patent/KR20010014020A/ko not_active Ceased
- 1998-06-18 BR BR9810450-0A patent/BR9810450A/pt not_active IP Right Cessation
- 1998-06-18 JP JP50374899A patent/JP2002504916A/ja not_active Ceased
- 1998-06-18 CA CA002294259A patent/CA2294259A1/en not_active Abandoned
- 1998-06-18 US US09/445,461 patent/US6335332B1/en not_active Expired - Fee Related
- 1998-06-18 ES ES98936361T patent/ES2247707T3/es not_active Expired - Lifetime
- 1998-06-18 TR TR1999/03148T patent/TR199903148T2/xx unknown
- 1998-06-19 HR HR97110200.9A patent/HRP980340A2/hr not_active Application Discontinuation
- 1998-06-19 AR ARP980102928A patent/AR018997A1/es not_active Application Discontinuation
- 1998-06-19 ZA ZA9805352A patent/ZA985352B/xx unknown
- 1998-06-19 MA MA25126A patent/MA24573A1/fr unknown
- 1998-06-23 CO CO98035555A patent/CO4940451A1/es unknown

Also Published As

Publication number	Publication date
TR199903148T2 (xx)	2000-04-21
WO1998058925A1 (en)	1998-12-30
CO4940451A1 (es)	2000-07-24
EP0989982B1 (de)	2005-08-17
CN1267296A (zh)	2000-09-20
DE69831233T2 (de)	2006-06-01
CN1295227C (zh)	2007-01-17
JP2002504916A (ja)	2002-02-12
BR9810450A (pt)	2000-09-05
ATE302200T1 (de)	2005-09-15
AU8539198A (en)	1999-01-04
AR018997A1 (es)	2001-12-26
US6335332B1 (en)	2002-01-01
EP0989982A1 (de)	2000-04-05
DE69831233D1 (de)	2005-09-22
KR20010014020A (ko)	2001-02-26
MA24573A1 (fr)	1998-12-31
ES2247707T3 (es)	2006-03-01
AU746853B2 (en)	2002-05-02
CA2294259A1 (en)	1998-12-30
HRP980340A2 (en)	1999-02-28

Publication	Publication Date	Title
ZA985352B (en)	1999-12-20	Barbituric acid derivatives with antimetastatic and antitumor activity.
ZA987037B (en)	2000-02-07	Benzylidene-1-3-dihydro-indol-2-one derivatives having anti-cancer activity.
AU3363499A (en)	1999-10-18	Nucleosides with antiviral and anticancer activity
PL343249A1 (en)	2001-07-30	Indole derivatives with antiviral activity
ZA9811339B (en)	1999-07-08	Benzamidine derivatives.
ZA986905B (en)	2000-01-31	Substituted quinazoline derivatives.
ZA962522B (en)	1997-09-29	Quinazoline derivatives.
HU9801587D0 (en)	1998-09-28	5h-thiazolo[3,2-a]pyrimidine derivatives
CY2328B1 (en)	2004-02-06	1,3-Dihydro-1-(phenylalkyl)-2H-imidazol-2-one derivatives having pdeiv and cytokine activity.
GB9522615D0 (en)	1996-01-03	4-Phenyl-4-oxo-butanoic acid derivatives with kynurenine-3-hydroxylase inhibiting activity
ZA969179B (en)	1997-05-29	4-Phenyl-4-oxo-2-butenoic acid derivatives with kynurenine-3-hydroxylase inhibiting activity
HUP0102681A3 (en)	2002-01-28	New guanidine derivatives with anticoagulant activity
AU8016398A (en)	1998-12-08	Peptides with antiviral activity
MXPA99001777A (es)	2003-08-10	Dihidropirones con actividad antiviral mejorada.
ZA989664B (en)	2000-04-25	3-substituted tetrahydropyrimidinone derivatives, their preparation and use.
AU1172599A (en)	1999-06-07	Compounds with antitumor activity
ZA977833B (en)	1998-03-02	N-substituted-2-amino-4-phenyl-4-oxo-butanoic acid derivatives with kynurenine-3-hydroxylate inhibitory activity.
PL327686A1 (en)	1998-12-21	Derivatives of @-amino 5,6-dichlorobenzimidazole exhibiting antiviral activity
ZA989571B (en)	2000-04-25	2-Substituted 1,2-Benzoisonthiazole derivatives, their preparation and use.
HUP0001306A3 (en)	2002-01-28	Corn pullulanase
AU7040798A (en)	1998-10-22	Pyrimidinone-1,3-oxathiolane derivatives with antiviral activity
ZA200006632B (en)	2001-06-01	Quinoline-aminomethyl-pyridyl derivatives with anti-helicobacter activity.
AU8526198A (en)	1999-02-22	Compounds with anti-ks and anti-hiv activity
AU8808098A (en)	1999-02-22	Bis-acridinecarboxamides having antitumor activity
GB0005108D0 (en)	2000-04-26	Glucose responsive -cell line